Warnex's Medical Laboratories Division Obtains ISO 15189 Accreditation

LAVAL, QUEBEC, Jun 29 (MARKET WIRE) --
Warnex Inc. (TSX: WNX) announced today that its Medical Laboratories
division has obtained ISO 15189:2007 accreditation by the Standards
Council of Canada (SCC). This accreditation is an international standard
for quality management systems for medical testing laboratories. Warnex
Medical Laboratories is only the second private laboratory in Canada to
obtain this accreditation.

"We are pleased and proud to have received this second ISO accreditation
for our Medical Laboratories division, demonstrating once again our
commitment to the highest standards of quality," said Mark Busgang,
President and CEO of Warnex. "We place great importance not only on the
quality of our specialized lab services, but also on their continuous
improvement. To this end, our dedicated staff worked diligently to
achieve ISO 15189 accreditation and continues to expend efforts towards
expanding our portfolio of specialized medical testing services."

The ISO 15189 standard addresses the quality management system of medical
laboratories to better serve the needs of both patients and clinical
personnel responsible for the care of those patients. The standard
encompasses provisions for the pre-analytical phase to the
post-analytical phase of medical laboratory services, including advice to
users, collection of patient samples, analysis of samples, interpretation
of test results, acceptable turnaround times, how testing is to be
provided in a medical emergency and the lab's role in the education and
training of health care staff.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting
public health by providing laboratory services to the pharmaceutical and
healthcare sectors. Warnex's analytical services division provides
pharmaceutical and biotechnology companies with a variety of quality
control services, including chemistry, chromatography, microbiology,
method development and validation, and stability studies. Warnex's
bioanalytical services division specializes in bioequivalence and
bioavailability studies for clinical trials. Warnex's medical
laboratories division focuses on genetic and biochemical testing for the
healthcare industry and has extensive expertise in genetic testing for
human identification, molecular diagnostics, and pharmacogenetics.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to
financial resources, government regulations, laboratory facilities,
suppliers, employees, key customers and business partners, foreign
currency risk, credit risk, liquidity risk, volatility of share price,
and other important factors that could cause actual results to differ
materially from those anticipated in the forward-looking statements,
please refer to the heading Risks and Uncertainties in Warnex's most
recent Management's Discussion and Analysis, which can be found at
www.sedar.com. Consequently, actual results may differ materially from
the anticipated results expressed in these forward-looking statements.

Contacts:
Warnex Inc.
Mark J. Busgang
President & CEO
450-663-6724 x 310
mbusgang@warnex.ca

Warnex Inc.
Catherine Sartoros
Communications Specialist
450-663-6724 x 277
csartoros@warnex.ca

Copyright 2009, Market Wire, All rights reserved.

-0-